SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Exelixis, Inc. (EXEL) -- Ignore unavailable to you. Want to Upgrade?


To: keokalani'nui who wrote (72)9/2/2004 4:41:39 PM
From: keokalani'nui  Respond to of 930
 
Sorry, phone call, partial post...to continue the thoughts

XL999 inhibits the FGFR, VEGFR, PDGFR and Flt3 RTKs and has activity against KIT and the FLT3 model of leukemia.

My personal goals for exel: Would like to see GSK supersize the deal 1/05, whispered early P1 results in anything 4/05, and a $120m financing at >$12 in May, pre-asco.